Jan Wehkamp

List of Publications by Year
in descending order

106 papers	10,567 citations	50276 46 h-index	32842 100 g-index
112 all docs	112 docs citations	112 times ranked	12109 citing authors

#	Article	IF	Citations
1	Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut, 2012, 61, 1693-1700.	12.1	1,295
2	Reduced Paneth cell Î±-defensins in ileal Crohn's disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18129-18134.	7.1	954
3	A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon. American Journal of Human Genetics, 2006, 79, 439-448.	6.2	487
4	NF-ÎºB- and AP-1-Mediated Induction of Human Beta Defensin-2 in Intestinal Epithelial Cells byEscherichia coliNissle 1917: a Novel Effect of a Probiotic Bacterium. Infection and Immunity, 2004, 72, 5750-5758.	2.2	437
5	Reduction of disulphide bonds unmasks potent antimicrobial activity of human Î²-defensin 1. Nature, 2011, 469, 419-423.	27.8	428
6	Human Î±-Defensin 6 Promotes Mucosal Innate Immunity Through Self-Assembled Peptide Nanonets. Science, 2012, 337, 477-481.	12.6	337
7	Intestinal barrier in inflammatory bowel disease. World Journal of Gastroenterology, 2014, 20, 1165.	3.3	309
8	<scp>A</scp> ntimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Molecular Medicine, 2013, 5, 1465-1483.	6.9	293
9	NOD2/CARD15 Mediates Induction of the Antimicrobial Peptide Human Beta-defensin-2. Journal of Biological Chemistry, 2006, 281, 2005-2011.	3.4	288
10	Induction of Human Î²-Defensin 2 by the Probiotic Escherichia coli Nissle 1917 Is Mediated through Flagellin. Infection and Immunity, 2007, 75, 2399-2407.	2.2	288
11	The Paneth Cell Î±-Defensin Deficiency of Ileal Crohnâ€™s Disease Is Linked to Wnt/Tcf-4. Journal of Immunology, 2007, 179, 3109-3118.	0.8	287
12	Inducible and Constitutive Î²-Defensins Are Differentially Expressed in Crohn's Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2003, 9, 215-223.	1.9	260
13	Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation, 2009, 77, 84-94.	1.9	229
14	Human Î²-defensin 2 but not Î²-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2002, 14, 745-752.	1.6	197
15	Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8772-8777.	7.1	183
16	Intestinal bacterial translocation in rats with cirrhosis is related to compromised paneth cell antimicrobial host defense. Hepatology, 2012, 55, 1154-1163.	7.3	164
17	Crohn's disease. European Journal of Gastroenterology and Hepatology, 2003, 15, 627-634.	1.6	151
18	Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. European Journal of Gastroenterology and Hepatology, 2006, 18, 615-621.	1.6	149

#	Article	IF	Citations
19	Paneth cell antimicrobial peptides: Topographical distribution and quantification in human gastrointestinal tissues. FEBS Letters, 2006, 580, 5344-5350.	2.8	147
20	Elevated Human Î²-Defensin-2 Levels Indicate an Activation of the Innate Immune System in Patients With Irritable Bowel Syndrome. American Journal of Gastroenterology, 2009, 104, 404-410.	0.4	146
21	Defensins and other antimicrobial peptides in inflammatory bowel disease. Current Opinion in Gastroenterology, 2007, 23, 370-378.	2.3	143
22	Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. Journal of Leukocyte Biology, 2004, 77, 460-465.	3.3	141
23	Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut, 2007, 56, 1240-1247.	12.1	138
24	Mechanisms of Disease: defensins in gastrointestinal diseases. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 406-415.	1.7	137
25	Genetic Variants of Wnt Transcription Factor TCF-4 (TCF7L2) Putative Promoter Region Are Associated with Small Intestinal Crohn's Disease. PLoS ONE, 2009, 4, e4496.	2.5	125
26	Intestinal Barrier Function and the Gut Microbiome Are Differentially Affected in Mice Fed a Western-Style Diet or Drinking Water Supplemented with Fructose. Journal of Nutrition, 2017, 147, 770-780.	2.9	118
27	Paneth's disease. Journal of Crohn's and Colitis, 2010, 4, 523-531.	1.3	115
28	Defensins and cathelicidins in gastrointestinal infections. Current Opinion in Gastroenterology, 2007, 23, 32-38.	2.3	113
29	Inflammatory Bowel Disease: Crohnâ€™s disease and ulcerative colitis. Deutsches Ärzteblatt International, 2016, 113, 72-82.	0.9	111
30	Inflammatory bowel disease: an impaired barrier disease. Langenbeck's Archives of Surgery, 2013, 398, 1-12.	1.9	110
31	Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohnâ€™s disease. Journal of Leukocyte Biology, 2007, 81, 907-915.	3.3	99
32	Human colonic mucus is a reservoir for antimicrobial peptides. Journal of Crohn's and Colitis, 2013, 7, e652-e664.	1.3	92
33	More than a marine propeller â€“ the flagellum of the probiotic Escherichia coli strain Nissle 1917 is the major adhesin mediating binding to human mucus. International Journal of Medical Microbiology, 2012, 302, 304-314.	3.6	78
34	A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. Journal of Microbiological Methods, 2006, 65, 335-345.	1.6	77
35	Crohn's disease-derived monocytes fail to induce Paneth cell defensins. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14000-14005.	7.1	71
36	Disulphide-reduced psoriasin is a human apoptosis-inducing broad-spectrum fungicide. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13039-13044.	7.1	67

#	Article	IF	Citations
37	From intestinal stem cells to inflammatory bowel diseases. World Journal of Gastroenterology, 2011, 17, 3198-203.	3.3	66
38	An Update Review on the Paneth Cell as Key to Ileal Crohn's Disease. Frontiers in Immunology, 2020, 11, 646.	4.8	63
39	Ubiquitously expressed Human Beta Defensin 1 (hBD1) forms bacteria-entrapping nets in a redox dependent mode of action. PLoS Pathogens, 2017, 13, e1006261.	4.7	63
40	Olfactomedin-4 is a glycoprotein secreted into mucus in active IBD. Journal of Crohn's and Colitis, 2012, 6, 425-434.	1.3	61
41	Defective Paneth Cellâ€"Mediated Host Defense in Pediatric Ileal Crohn's Disease. American Journal of Gastroenterology, 2010, 105, 452-459.	0.4	58
42	A New Look at Crohn's Disease: Breakdown of the Mucosal Antibacterial Defense. Annals of the New York Academy of Sciences, 2006, 1072, 321-331.	3.8	55
43	Human Î²-Defensin 2 Mediated Immune Modulation as Treatment for Experimental Colitis. Frontiers in Immunology, 2020, 11, 93.	4.8	52
44	Results of the 2nd Scientific Workshop of the ECCO (III): Basic mechanisms of intestinal healing. Journal of Crohn's and Colitis, 2012, 6, 373-375.	1.3	50
45	Innate antimicrobial host defense in small intestinal Crohn's disease. International Journal of Medical Microbiology, 2010, 300, 34-40.	3.6	47
46	Family history of CrohnÊ¼s disease is associated with an increased risk for CrohnÊ¼s disease of the pouch. Inflammatory Bowel Diseases, 2009, 15, 163-170.	1.9	46
47	Antibacterial activity of human defensins on anaerobic intestinal bacterial species: a major role of HBD-3. Microbes and Infection, 2009, 11, 384-393.	1.9	46
48	Crohnâ€™s disease-Defect in innate defence. World Journal of Gastroenterology, 2008, 14, 5499.	3.3	46
49	In vivo gene expression profiling of human intestinal epithelial cells: analysis by laser microdissection of formalin fixed tissues. BMC Genomics, 2008, 9, 209.	2.8	45
50	Association of a Functional Variant in the Wnt Co-Receptor LRP6 with Early Onset Ileal Crohn's Disease. PLoS Genetics, 2012, 8, e1002523.	3.5	44
51	Bacteria Regulate Intestinal Epithelial Cell Differentiation Factors Both In Vitro and In Vivo. PLoS ONE, 2013, 8, e55620.	2.5	44
52	Human Defensins in Crohnâ€™s Disease. , 2005, 86, 42-54.		43
53	Bifidobacterium bifidum in a rat model of necrotizing enterocolitis: antimicrobial peptide and protein responses. Pediatric Research, 2012, 71, 546-551.	2.3	43
54	A Peptide Derived from the Highly Conserved Protein GAPDH Is Involved in Tissue Protection by Different Antifungal Strategies and Epithelial Immunomodulation. Journal of Investigative Dermatology, 2013, 133, 144-153.	0.7	41

#	Article	IF	Citations
55	TCF-1-mediated Wnt signaling regulates Paneth cell innate immune defense effectors HD-5 and -6: implications for Crohn's disease. American Journal of Physiology - Renal Physiology, 2014, 307, G487-G498.	3.4	41
56	Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins. International Journal of Medical Microbiology, 2012, 302, 276-287.	3.6	40
57	Intestinal barrier analysis by assessment of mucins, tight junctions, and Î±-defensins in healthy C57BL/6J and BALB/cJ mice. Tissue Barriers, 2016, 4, e1208468.	3.2	40
58	Paneth cells and the innate immune response. Current Opinion in Gastroenterology, 2006, 22, 644-650.	2.3	39
59	Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Research, 2018, 7, 1207.	1.6	38
60	Antimicrobial Peptides in Gastrointestinal Inflammation. International Journal of Inflammation, 2010, 2010, 1-11.	1.5	37
61	Defective Antibacterial Barrier in Inflammatory Bowel Disease. Digestive Diseases, 2013, 31, 310-316.	1.9	35
62	Serum Procalcitonin Differentiates Inflammatory Bowel Disease and Self-limited Colitis. Inflammatory Bowel Diseases, 2004, 10, 229-233.	1.9	34
63	Crosstalk between microbiota, pathogens and the innate immune responses. International Journal of Medical Microbiology, 2016, 306, 257-265.	3.6	34
64	Gastric Antimicrobial Peptides Fail to Eradicate Helicobacter pylori Infection Due to Selective Induction and Resistance. PLoS ONE, 2013, 8, e73867.	2.5	33
65	NOD2/CARD15 Gene Variants Are Linked to Failure of Antibiotic Treatment in Perianal Fistulating Crohn's Disease. American Journal of Gastroenterology, 2008, 103, 1197-1202.	0.4	29
66	Antimicrobial host defense in the upper gastrointestinal tract. European Journal of Gastroenterology and Hepatology, 2008, 20, 1151-1158.	1.6	23
67	High Demand for Psychotherapy in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 1796-1802.	1.9	23
68	Human Paneth cell Î±-defensin-5 treatment reverses dyslipidemia and improves glucoregulatory capacity in diet-induced obese mice. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E42-E52.	3.5	22
69	Waking the wimp: Redox-modulation activates human beta-defensin 1. Gut Microbes, 2011, 2, 262-266.	9.8	21
70	Management of Crohn's disease â€“ are guidelines transferred to clinical practice?. United European Gastroenterology Journal, 2015, 3, 371-380.	3.8	20
71	In the Wnt of Paneth Cells: Immune-Epithelial Crosstalk in Small Intestinal Crohnâ€™s Disease. Frontiers in Immunology, 2017, 8, 1204.	4.8	20
72	Tacrolimus Suppositories in Therapy-Resistant Ulcerative Proctitis. Inflammatory Intestinal Diseases, 2018, 3, 116-124.	1.9	20

#	Article	IF	Citations
73	Proteolytic Degradation of reduced Human Beta Defensin 1 generates a Novel Antibiotic Octapeptide. Scientific Reports, 2019, 9, 3640.	3.3	20
74	Antimicrobial Peptides in the Skin. New England Journal of Medicine, 2003, 348, 361-363.	27.0	19
75	Diminished Expression of Apical Sodium-Dependent Bile Acid Transporter in Gallstone Disease Is Independent of Ileal Inflammation. Digestion, 2008, 78, 52-59.	2.3	19
76	Antimicrobial Activity of High-Mobility-Group Box 2: a New Function to a Well-Known Protein. Antimicrobial Agents and Chemotherapy, 2013, 57, 4782-4793.	3.2	19
77	Human Î²â€defensinâ€2 suppresses key features of asthma in murine models of allergic airways disease. Clinical and Experimental Allergy, 2021, 51, 120-131.	2.9	19
78	Ustekinumab is effective in biological refractory Crohnâ€™s disease patientsâ€“regardless of approval study selection criteria. Intestinal Research, 2019, 17, 340-348.	2.6	18
79	NOD2 mutation and mice: no Crohn's disease but many lessons to learn. Trends in Molecular Medicine, 2005, 11, 307-309.	6.7	15
80	Innate immunity includes defensins. Annals of Gastroenterology, 2012, 25, 3-5.	0.6	15
81	Recent advances in understanding and managing Crohnâ€™s disease. F1000Research, 2016, 5, 2896.	1.6	14
82	Microbiome and chronic inflammatory bowel diseases. Journal of Molecular Medicine, 2017, 95, 21-28.	3.9	14
83	Intestinal manipulation affects mucosal antimicrobial defense in a mouse model of postoperative ileus. PLoS ONE, 2018, 13, e0195516.	2.5	14
84	Hostâ€“microbe interaction: mechanisms of defensin deficiency in Crohnâ€™s disease. Expert Review of Anti-Infective Therapy, 2007, 5, 1049-1057.	4.4	13
85	Innate antimicrobial immunity in inflammatory bowel diseases. Expert Review of Clinical Immunology, 2010, 6, 809-818.	3.0	13
86	Î²-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor. Frontiers in Immunology, 2018, 9, 1735.	4.8	12
87	Human Î²-Defensin 2 Mutations Are Associated With Asthma and Atopy in Children and Its Application Prevents Atopic Asthma in a Mouse Model. Frontiers in Immunology, 2021, 12, 636061.	4.8	12
88	Fragmentation of Human Neutrophil Î±-Defensin 4 to Combat Multidrug Resistant Bacteria. Frontiers in Microbiology, 2020, 11, 1147.	3.5	11
89	Histone deacetylase-mediated regulation of the antimicrobial peptide hBD2 differs in intestinal cell lines and cultured tissue. Scientific Reports, 2018, 8, 12886.	3.3	10
90	The human Î±-defensin-derived peptide HD5(1â€“9) inhibits cellular attachment and entry of human cytomegalovirus. Antiviral Research, 2020, 177, 104779.	4.1	10

#	Article	IF	Citations
91	Is there a role for defensins in IBD?. Inflammatory Bowel Diseases, 2008, 14, S85-S87.	1.9	9
92	Paneth cell function - Implications in pediatric Crohn disease. Gut Microbes, 2011, 2, 47-51.	9.8	9
93	Medical Therapy of Perianal Crohn's Disease. Visceral Medicine, 2015, 31, 265-272.	1.3	8
94	Human Endogenous Retroviruses: Residues of Ancient Times Are Differentially Expressed in Crohnâ€™s Disease. Inflammatory Intestinal Diseases, 2018, 3, 125-137.	1.9	6
95	Coding variants in NOD-like receptors: An association study on risk and survival of colorectal cancer. PLoS ONE, 2018, 13, e0199350.	2.5	6
96	Infodemiology of Crohnâ€™s disease and Ulcerative colitis using GoogleÂTrends â€“ an approach to investigate patient needs. Zeitschrift Fur Gastroenterologie, 2020, 58, 224-233.	0.5	6
97	Low-grade appendiceal mucinous neoplasm (LAMN) â€“ 3-year endoscopic follow-up underlines benign course ofÂLAMN type 1. Zeitschrift Fur Gastroenterologie, 2017, 55, 149-152.	0.5	5
98	Curbing gastrointestinal infections by defensin fragment modifications without harming commensal microbiota. Communications Biology, 2021, 4, 47.	4.4	4
99	Is there a role for defensins in IBD?. Inflammatory Bowel Diseases, 2008, 14, S85-S87.	1.9	2
100	Antimicrobial Peptides in the Gut. , 2016, , 67-88.		1
101	Enterocutaneous fistula in severely active Crohnâ€™s disease: preoperative anti-TNF alpha treatment to limit bowel resectionâ€”report of a case. International Journal of Colorectal Disease, 2019, 34, 369-373.	2.2	1
102	Antimicrobial Peptides and Inflammatory Bowel Disease. , 2013, , 255-273.		1
103	Measurement of antimicrobial activity under reducing conditions in a modified radial diffusion assay. Protocol Exchange, 0, , .	0.3	1
104	Production of recombinant hBD-1 in Escherichia coli and its specific polyclonal antibody in rabbits. Protocol Exchange, 0, , .	0.3	1
105	Influence of NOD2 Variants on Trichuris suis ova Treatment Outcome in Crohnâ€™s Disease. Frontiers in Pharmacology, 2018, 9, 764.	3.5	0
106	Netzbildung als Abwehrstrategie des menschlichen KÃ¶rpers. BioSpektrum, 2018, 24, 146-148.	0.0	0